OQS
NKTR icon

Occudo Quantitative Strategies’s Nektar Therapeutics NKTR Stock Holding History

Occudo Quantitative Strategies’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$761K Buy
+8,948
New +$509K 0.04% 439
2023
Q4 		– Sell
-1,916
Closed -$17.1K – 1067
2023
Q3 		$17.1K Sell
1,916
-8,094
-81% -$77.9K ﹤0.01% 925
2023
Q2 		$86.4K Hold
10,010
– – 0.01% 938
2023
Q1 		$106K Sell
10,010
-6,398
-39% -$194K 0.01% 815
2022
Q4 		$556K Sell
16,408
-4,399
-21% -$213K 0.06% 470
2022
Q3 		$999K Buy
20,807
+1,441
+7% +$85.7K 0.08% 399
2022
Q2 		$1.1M Buy
19,366
+12,617
+187% +$796K 0.09% 354
2022
Q1 		$546K Buy
6,749
+4,560
+208% +$675K 0.05% 613
2021
Q4 		$444K Sell
2,189
-328
-13% -$71.2K 0.04% 655
2021
Q3 		$678K Buy
2,517
+1,843
+273% +$443K 0.08% 423
2021
Q2 		$174K Buy
+674
New +$187K 0.03% 737
2021
Q1 		– Sell
-1,576
Closed -$402K – 871
2020
Q4 		$402K Buy
+1,576
New +$407K 0.13% 318

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Occudo Quantitative Strategies's NKTR Position: Q1 2026 in Review

Occudo Quantitative Strategies opened a new position in Nektar Therapeutics (NKTR) in Q1 2026: 8,948 shares worth $761K. The stake represents 0.04% of the portfolio and ranks #439 among its holdings. This is a return to the name: Occudo Quantitative Strategies previously reported a position in NKTR as recently as Q3 2023.

Occudo Quantitative Strategies first reported a position in NKTR in Q4 2020 and has held it in 12 quarters since. The position peaked at $1.1M in Q2 2022. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • Occudo Quantitative Strategies held 8,948 shares of Nektar Therapeutics worth $761K as of Q1 2026.
  • Nektar Therapeutics was a new Occudo Quantitative Strategies position in Q1 2026.
  • Nektar Therapeutics made up 0.04% of Occudo Quantitative Strategies's portfolio in Q1 2026, its #439 holding.
  • Occudo Quantitative Strategies first reported a position in Nektar Therapeutics in Q4 2020 and has held it in 12 quarters since.
  • Occudo Quantitative Strategies's Nektar Therapeutics position peaked at $1.1M in Q2 2022.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Occudo Quantitative Strategies's 13F filing for Q1 2026, filed 15 May 2026.